Yes. Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) both offer savings cards and patient assistance programs. Savings cards can reduce copays significantly for commercially insured patients. Patient assistance programs (PAPs) provide free medication to qualifying uninsured or underinsured individuals based on income. Eligibility and terms change frequently—check the manufacturers' websites directly. These programs are one reason to explore prescription access before or alongside gray-market use.